SPARC — Sun Pharma Advanced Research Co Income Statement
0.000.00%
- IN₹52.86bn
- IN₹55.51bn
- IN₹717.70m
Annual income statement for Sun Pharma Advanced Research Co, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2,530 | 1,372 | 2,388 | 755 | 718 |
Cost of Revenue | |||||
Gross Profit | 2,163 | 1,065 | 2,045 | 350 | 487 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3,987 | 3,333 | 4,624 | 4,870 | 4,073 |
Operating Profit | -1,457 | -1,961 | -2,236 | -4,115 | -3,355 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -1,511 | -2,034 | -2,226 | -3,868 | -3,428 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1,511 | -2,034 | -2,226 | -3,872 | -3,425 |
Net Income Before Extraordinary Items | |||||
Net Income | -1,511 | -2,034 | -2,226 | -3,872 | -3,425 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1,511 | -2,034 | -2,226 | -3,872 | -3,425 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -5.78 | -7.92 | -7.81 | -11.9 | -10.6 |